Clinical Trial Update: Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer . [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for a three-drug combination (ramucirumab, nanoliposomal irinotecan, and trifluridine/tipiracil) being studied in second-line metastatic g…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma

Drugs mentioned

• Cyramza (ramucirumab)
• Lonsurf (trifluridine/tipiracil)
• Onivyde (irinotecan hydrochloride liposome injection)

Snippet

Sponsor: National Health Research Institutes, Taiwan | Conditions: Metastatic Gastric Adenocarcinoma, Second Line | Phase 1, Phase 2 | Status: RECRUITING